Pro-Pharmaceuticals Inc. is the latest struggling biotech company to face a major cash crunch, even as it comes close to submitting its lead compound to treat cancer for FDA approval.
Pro-Pharmaceuticals Inc. is the latest struggling biotech company to face a major cash crunch, even as it comes close to submitting its lead compound to treat cancer for FDA approval.